Citi Raises Gilead (GILD) Price Target Ahead of Q1 Biopharma Preview [Yahoo! Finance]
Jim Cramer on Gilead Sciences: “I'd Hold On to It” [Yahoo! Finance]
Gilead Sciences (GILD) had its price target raised by The Goldman Sachs Group, Inc. from $125.00 to $130.00. They now have a "neutral" rating on the stock.
Gilead Receives All Required Regulatory Approvals for the Acquisition of Arcellx and Extends Tender Offer
Gilead Sciences' HIV Drug Shows Weaker-Than-Expected Persistence Nine Months After Launch, RBC Says [Yahoo! Finance]